Growing Families conferences in London and Dublin, March 2020
Page URL: https://www.bionews.org.uk/page_89857

Study confirms schizophrenia gene link

24 October 2005
By BioNews
Appeared in BioNews 331

A new study provides more evidence that a gene which affects levels of a key brain chemical is involved in schizophrenia. A team based at Stanford University in California, US, found that children with a single, 'low-activity' copy of a gene called COMT (catechol-O-methyl transferase) are at higher risk of developing psychotic symptoms than those with a single 'high-activity' copy of the gene. The researchers, who published their findings online in the journal Nature Neuroscience, say they hope that the research will lead to new treatments for schizophrenia, and new ways of detecting people at high risk of the condition.

Schizophrenia is one of several brain disorders thought to involve an imbalance in levels of dopamine, a key brain communication chemical. Too much or too little dopamine can dramatically affect a person's thought processes, movement, or behaviour. The COMT gene makes a protein that breaks down dopamine in the brain, and comes in two different versions - the more active 'val' form, and a less active 'met' variety.

In the latest study, the scientists looked at children born with a small part of one of their two chromosome 22s missing, or deleted. This deletion encompasses the COMT gene, as well as several other genes. It causes a condition known as velocardiofacial syndrome, which is characterised by special facial features, heart defects and cleft problems. The condition also raises the risk of developing a psychotic disorder such as schizophrenia to 30 per cent, compared to the average population risk of one per cent.

The team wanted to investigate if, in children born with a copy of COMT missing, alternative versions of the remaining gene affected the risk of psychotic symptoms. So the scientists studied 24 children born with a chromosome 22 deletion, and compared them with 23 children who had an unknown developmental disorder. At the beginning of the study, none of the participants showed any signs of psychosis. However, five years later, when they were teenagers, seven (29 per cent) of those with the deletion had developed a psychotic disorder, compared to just one in the control group. Furthermore, the children with a deletion and a low activity 'met' version of COMT on their other chromosome 22 had more severe symptoms, compared to those born with a deletion and a high activity 'val' version.

The scientists think that having just one, low activity version of COMT can lead to damagingly high levels of dopamine in the developing brain of a child with velocardiofacial syndrome. They liken the process to dialing-in a radio station - dopamine levels need to be precisely tuned, not too much or too little, to maximise the signal and minimise the noise. Team leader Allan Reiss said: 'Although this deletion probably causes less than five per cent of schizophrenia cases, it's the only well-defined genetic risk factor we have right now', said, adding 'in the future, researchers will likely discover multiple causes of this disorder, with complex interactions between genetic and environmental risk factors'.

SOURCES & REFERENCES
Dopamine link to psychiatric and neurological disorders
News-Medical.net |  23 October 2005
Gene may help doctors identify patients at risk of schizophrenia
The Independent |  24 October 2005
Teens with deletion syndrome confirm gene's role in psychosis
EurekaAlert |  23 October 2005
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
20 October 2008 - by Stuart Scott 
A study of almost 500 individuals with schizophrenia has revealed 12 genetic variants thought to increase risk for the disease. Writing in Nature Genetics, the researchers, based at Cardiff University, Wales, UK, revealed that one variant, on chromosome 2, held particular significance. The researchers scanned the genomes...
1 August 2008 - by Ailsa Stevens 
Three independent studies have identified gene variants which contribute significantly to schizophrenia risk, taking steps towards understanding the cause of this highly complex condition which affects 1 in 100 people. Two of the three gene variants discovered were rare, but conferred 12 and 15 percent higher risks...
31 March 2008 - by Ailsa Stevens 
Two independent studies published in the journal Science this week suggest that many rare gene mutations may be responsible for causing schizophrenia, challenging the widely held theory that combinations of several relatively common mutations are to blame. The researchers found that very rare genetic disruptions, often unique...
10 December 2007 - by Ailsa Stevens 
US researchers at the Feinstein Institute for Medical Research last week reported the discovery of nine new genetic markers for schizophrenia. The study - published in the journal Proceedings of the National Academy of Sciences - used a novel whole genome scanning method to identify sections of genetic code...
5 November 2006 - by Dr Jess Buxton 
UK researchers have identified a genetic variation associated with an increased risk of schizophrenia in people with a strong family history of the condition. The team, based at Edinburgh University, discovered that individuals who inherit a particular version of the neuregulin (NRG1) gene have nearly three...
15 April 2005 - by BioNews 
A person's risk of developing a psychotic illness such as schizophrenia after smoking cannabis as a teenager is affected by their genetic make-up, say UK researchers. A new study to be published in the journal Biological Psychiatry shows that a variant of the COMT gene is linked to a five-fold...
4 June 2001 - by BioNews 
Scientists from the US National Institute of Mental Health (NIMH) have found a gene variation that may increase the risk of developing schizophrenia. The gene, called COMT (catecho-o-methytransferase) appears to control levels of the chemical dopamine in the brain. Lower levels of dopamine can affect performance in memory tasks and...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.